Exam uretral spinchter dilation procedure and indication, causes of recurrent uti in older female, treatment of neurological bladder
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Searching the Web
urethral dilation procedure technique indications female urology 2024
Reading File
Searching the Web
recurrent UTI older women risk factors causes pelvic floor prolapse 2024
1. Urethral (Sphincter) Dilation - Procedure and Indications
What is Urethral Dilation?
Urethral dilation is a procedure to widen the urethra by progressively inserting dilating instruments (bougies, Hegar dilators, Otis urethrotome, or balloon catheters) to a target French size. In the context of the external urethral sphincter, the procedure addresses obstruction at the level of the striated or smooth sphincter mechanism. Per the EAU Urethral Strictures Guidelines (2024), urethral dilation to 24-41 Fr is the recommended first-line treatment for female urethral stricture (FUS).
Indications
| Indication | Notes |
|---|---|
| Urethral stricture / stenosis | Most common indication (97% of cases in UK surveys); often idiopathic or post-inflammatory |
| Neurogenic bladder - urinary retention | Dilation was historically used to reduce outflow resistance in neurogenic bladder (Campbell-Walsh Urology notes urethral dilation as a described treatment) |
| Female urethral obstruction with LUTS | Frequency, urgency, poor flow, incomplete emptying - after excluding other causes |
| Recurrent UTI thought to be caused by obstruction | Empirical use in children and women; based on the distal urethral ring hypothesis (Lyon et al.) |
| Post-catheterization or post-instrumentation stenosis | Iatrogenic narrowing after prolonged catheter use or prior urologic procedures |
| Meatal stenosis | Congenital or secondary narrowing of the meatus |
| Facilitating catheterization when direct passage is blocked | Used when standard catheter cannot pass due to sphincter spasm or stricture |
Procedure - Step by Step
Preparation
- Patient in lithotomy position (female) or supine (male)
- Urethroscopy or urethrogram first to confirm and localize stricture (VCUG or video urodynamics recommended before dilation in females per EAU guidelines)
- Topical lubricant/anesthetic gel (lidocaine 2%) instilled into urethra
- Sterile technique; antibiotic prophylaxis given
Technique
- Progressive dilation with sounds (bougies a boule or Hegar dilators): Start with a dilator that passes easily, then advance in size incrementally (e.g., 14 Fr → 16 Fr → ... → 24-41 Fr in females). Never force a dilator.
- Balloon dilation: A balloon catheter is passed to the stricture site and inflated to a preset pressure, dilating the narrowed segment. Used for posterior urethral strictures, bladder neck contractures, and strictures adjacent to an artificial urinary sphincter.
- Otis urethrotome (internal urethrotomy): A cutting instrument that incises the urethra at the 12 o'clock position under direct vision, preferred in some centers over blunt dilation.
- After dilation: A urethral catheter may be left in place temporarily; patient may be taught intermittent self-dilation (ISD) with a 16-18 Fr catheter weekly to maintain patency after first recurrence.
Post-Procedure Management (per EAU 2024)
- First recurrence of female urethral stricture: repeat dilation + initiate planned weekly ISD (16-18 Fr) - achieves patency rates of ~97% at 6-21 months
- Second recurrence or failure of ISD: refer for urethroplasty (buccal mucosal graft or dorsal/ventral onlay flap)
- Dilation alone has a stricture-free rate of only ~40% at 36 months; ISD greatly improves maintenance
Contraindications / Cautions
- Suspected urethral trauma or disruption (do urethrogram first)
- Active urinary tract infection (treat first)
- External sphincter spasm (can cause spurious resistance at ~16 cm from meatus in males) - requires patience, not force
- Urethral carcinoma
2. Causes of Recurrent UTI in Older Females
Recurrent UTI is defined as ≥2 episodes in 6 months or ≥3 episodes in 12 months, confirmed by positive urine cultures. Older/postmenopausal women have a distinct and different risk profile from younger women.
Anatomical / Structural Causes
| Cause | Mechanism |
|---|---|
| Pelvic organ prolapse (POP) / Cystocele | Distortion of the lower urinary tract, impaired bladder emptying, elevated post-void residual (PVR) |
| Elevated post-void residual (PVR >30-50 mL) | Static urine acts as a culture medium; independent risk factor even without prolapse |
| Urethral stenosis | Outflow obstruction leading to incomplete voiding |
| Bladder diverticula or lesions | Areas of stagnant urine not adequately flushed during voiding |
| Urinary fistula | e.g., vesicovaginal fistula - constant source of bacterial contamination |
Hormonal Causes
| Cause | Mechanism |
|---|---|
| Estrogen deficiency (postmenopause) | Loss of lactobacilli from vaginal flora → rise in vaginal pH → colonization by uropathogens (E. coli, Klebsiella); note that systemic estrogen has NOT been shown to reduce UTI risk, but topical vaginal estrogen may have a modest benefit in highly recurrent cases |
| Vaginal atrophy (atrophic vaginitis) | Thinning of urogenital epithelium, decreased local immunity |
Behavioral / Host Factors
| Cause | Mechanism |
|---|---|
| Prior UTI history before menopause | Single strongest risk factor for recurrent UTI in postmenopausal women (Brenner & Rector's Kidney) |
| Spermicide/diaphragm use | Kills lactobacilli (more relevant to premenopausal women, less so in older women) |
| Sexual activity | Less of an independent factor in postmenopausal women than in younger women |
| Genetic susceptibility | Increased frequency in first-degree female relatives with recurrent UTI history |
Urologic / Medical Causes
| Cause | Mechanism |
|---|---|
| Neurogenic bladder dysfunction | Incomplete emptying, high PVR, catheter use (DM, MS, Parkinson's, stroke) |
| Indwelling catheter (urethral or suprapubic) | Direct bacterial conduit into bladder; biofilm formation |
| Urinary calculi (kidney stones, bladder stones) | Nidus for persistent bacterial colonization |
| Diabetes mellitus | Glycosuria (bacterial growth medium), impaired neutrophil function, autonomic neuropathy → bladder hypotonicity |
| Immunosuppression | Reduced ability to clear ascending pathogens |
| Recent urologic surgery or cystoscopy | Instrumentation introduces bacteria and disrupts mucosal barrier |
| Incomplete antibiotic treatment of prior UTI | Persistence of virulent E. coli strains in gut or vaginal flora reservoir |
Microbiology Note
- In older women, Klebsiella pneumoniae is isolated in 10-15% of cases (vs. <5% in premenopausal women)
- E. coli remains dominant (80-85%); reinfection with similar strains suggests incomplete eradication from bowel/vaginal reservoirs
- Enterococcus and group B Streptococcus more common than in younger women
3. Treatment of Neurogenic Bladder
The overarching goal of treatment, per both Comprehensive Clinical Nephrology 7e and Campbell-Walsh-Wein Urology, is: maintain low intravesical pressures to protect the upper urinary tract (kidneys).
Principles of Management
Patients with a small, low-volume, high-pressure bladder with a tight urethral sphincter are at greatest risk of upper tract deterioration and GFR loss. Treatment must be tailored to the type of dysfunction:
- Failure to store (overactive/spastic bladder): reduce detrusor overactivity
- Failure to empty (underactive/areflexic bladder): facilitate bladder emptying
Conservative / Behavioral
- Timed voiding / bladder training - scheduled voiding intervals to minimize overdistension
- Fluid management - restrict evening fluids to reduce nighttime incontinence
- Biofeedback - for partially intact voluntary control of striated sphincter
Catheterization (First-Line for Emptying Failure)
| Method | Indication | Notes |
|---|---|---|
| Clean Intermittent Catheterization (CIC) | Gold standard for incomplete emptying | Preserves urethral integrity; associated with reduced recurrent UTI when frequency is adequate (every 4-6 hrs) |
| Indwelling urethral catheter | Short-term or palliative when CIC not feasible | Higher UTI and bladder cancer risk long-term |
| Suprapubic catheter (SPC) | Long-term catheterization, urethral damage, or patient preference | Preferred over urethral catheter for chronic drainage |
Pharmacologic Therapy
Reducing Detrusor Overactivity (Failure to Store)
| Drug Class | Examples | Action |
|---|---|---|
| Antimuscarinics (anticholinergics) | Oxybutynin, tolterodine, solifenacin, trospium | Block M2/M3 muscarinic receptors; reduce involuntary detrusor contractions. Most commonly recommended first-line |
| β3-adrenergic agonists | Mirabegron | Relaxes detrusor smooth muscle; useful when antimuscarinics are not tolerated |
| Combined antimuscarinics + CIC | Standard combination | Most commonly recommended medical therapy; results sometimes unsatisfactory requiring escalation |
Reducing Outlet Resistance (Failure to Empty / DSD)
| Drug Class | Examples | Action |
|---|---|---|
| α-adrenergic antagonists | Tamsulosin, alfuzosin, prazosin | Relax smooth sphincter/bladder neck; reduce outflow resistance |
| Baclofen / benzodiazepines / dantrolene | - | Relax striated sphincter in detrusor-sphincter dyssynergia (DSD) |
| Botulinum toxin A (intrasphincteric) | OnabotA | Injected into external urethral sphincter to reduce DSD |
Minimally Invasive / Procedural
| Procedure | Indication |
|---|---|
| Intravesical Botulinum Toxin A (onabotulinum toxin-A / Botox) | Neurogenic detrusor overactivity refractory to antimuscarinics; injected cystoscopically into detrusor muscle (100-200 U); reduces urgency, incontinence, and intravesical pressure; repeat every 6-9 months |
| Sacral Neuromodulation (SNM) | Urgency-frequency, urge incontinence, urinary retention; modulates sacral nerve roots (S2-S4) via implanted electrode; can help both storage and emptying dysfunction in selected patients |
| Intravesical electrical stimulation (IVES) | Partially intact bladder sensation/detrusor function; limited evidence |
| Urethral sphincterotomy | Males with DSD causing dangerously high detrusor pressures; converts bladder to low-pressure conduit with condom catheter drainage |
| Urethral dilation | Historical use in neurogenic bladder to reduce outlet resistance |
Surgical Options
| Surgery | Indication |
|---|---|
| Augmentation cystoplasty (enterocystoplasty) | Small, fibrotic, high-pressure bladder not responding to medical/Botox therapy; bowel segment (usually ileum) used to increase bladder capacity and reduce pressure; always combined with CIC post-op |
| Bladder neck procedures | Incision or resection of bladder neck/smooth sphincter in selected cases |
| Urinary diversion | End-stage: ileal conduit or continent reservoir when all else fails |
| Artificial urinary sphincter (AUS) | Stress incontinence from sphincter weakness in neurogenic bladder |
Management Algorithm Summary
Neurogenic bladder diagnosed
│
▼
Urodynamics (essential to classify)
│
┌────┴────┐
Overactive Underactive
(storage) (emptying)
│ │
Antimuscarinics CIC (first-line)
± β3-agonist ± α-blocker
│
If refractory:
Intravesical Botox
│
If still refractory:
Sacral neuromodulation
│
If all fail:
Augmentation cystoplasty
± Urinary diversion
Sources: Campbell-Walsh-Wein Urology (multiple sections); Brenner and Rector's The Kidney 2-volume set, pp. 1630-1632; Comprehensive Clinical Nephrology 7e, p. 882; EAU Urethral Strictures Guidelines 2024; [Roberts and Hedges' Clinical Procedures in Emergency Medicine*]
Unwilling urine voiding after uretral spincter dilation procedure. What are the treatments
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
I now have comprehensive information to give a complete answer. Let me compile it.
Involuntary Urine Voiding (Urinary Incontinence) After Urethral Sphincter Dilation - Treatment
Understanding the Problem
Urethral dilation - especially over-aggressive dilation or repeated dilations - can damage the external urethral sphincter mechanism, resulting in:
- Stress Urinary Incontinence (SUI): Urine leaks with increased intra-abdominal pressure (coughing, sneezing, exercise, lifting) - due to intrinsic sphincter deficiency (ISD) or loss of urethral support
- Urgency Urinary Incontinence (UUI): Sudden compelling urge followed by involuntary leakage - may be triggered by detrusor overactivity secondary to post-procedure irritation or bladder instability
- Mixed Urinary Incontinence: Both components together - the most bothersome form
The EAU guidelines note that new-onset SUI (1.4%) is a recognized complication after urethral dilation in females, though rare when performed correctly.
Step 1 - Assessment Before Treatment
Before treatment, classify the type of incontinence:
- History and voiding diary (timing, triggers, volume, frequency)
- Cough stress test (demonstrates SUI on examination)
- Post-void residual (PVR) measurement (rule out overflow from incomplete emptying)
- Urinalysis/urine culture (exclude UTI as a contributing cause)
- Urodynamics (if diagnosis is unclear, mixed symptoms, or before surgical planning) - distinguishes SUI from UUI from overflow, and assesses sphincter function
Treatment - Organized by Level
A. Conservative (Non-Pharmacologic) - First-Line for All Types
| Intervention | Mechanism | Evidence |
|---|---|---|
| Pelvic Floor Muscle Training (PFMT / Kegel exercises) | Strengthens the levator ani and external urethral sphincter; restores passive urethral closure; cornerstone of behavioral treatment | First-line for SUI and UUI; effective in up to 70% of SUI cases |
| Bladder retraining | Timed voiding at gradually extended intervals; desensitizes urgency triggers | First-line for UUI/OAB |
| Prompted voiding | Scheduled voiding to pre-empt urgency episodes (especially in older or cognitively impaired patients) | Useful in elderly |
| Biofeedback | Real-time feedback to improve voluntary sphincter control during PFMT | Adjunct to PFMT |
| Weight loss (if obese) | Reduces mechanical load on pelvic floor | Reduces SUI episodes by ~50% in obese women |
| Fluid management | Avoid excessive fluid intake and bladder irritants (caffeine, alcohol, carbonated drinks) | Simple, effective first step |
| Incontinence pads/protective garments | Symptom management while definitive treatment is underway | Not curative but essential for QOL |
B. Intravaginal / Mechanical Devices
| Device | Use | Notes |
|---|---|---|
| Pessary (incontinence ring or dish) | SUI - supports urethrovesical junction and elevates bladder neck | Good option for women not fit for surgery; removable, reversible |
| Urethral inserts / occlusive devices | Worn in the urethra to physically block leakage; removed before voiding | Patient-controlled; suitable for activity-related leakage |
C. Pharmacologic Treatment
For Stress Urinary Incontinence (sphincter-related, post-dilation)
| Drug | Mechanism | Notes |
|---|---|---|
| Duloxetine (SNRI) | Increases resting tone of external urethral sphincter via pudendal nerve stimulation (serotonin and norepinephrine pathways in Onuf's nucleus) | ~50% reduction in episodes; used in moderate SUI not wanting surgery; nausea is common side effect |
| Topical vaginal estrogen (postmenopausal women) | Restores urogenital atrophy, improves urethral mucosal coaptation | Useful adjunct, especially when atrophic vaginitis co-exists with incontinence |
| Alpha-adrenergic agonists (e.g., pseudoephedrine) | Increase smooth sphincter tone | Limited use due to cardiovascular side effects; rarely prescribed now |
For Urgency Urinary Incontinence / Overactive Bladder component
| Drug | Mechanism | Notes |
|---|---|---|
| Antimuscarinics - Oxybutynin, Tolterodine, Solifenacin, Trospium, Darifenacin | Block M2/M3 muscarinic receptors → reduce detrusor overactivity | First-line pharmacologic treatment for UUI; note dry mouth, constipation, cognitive effects (avoid in elderly: prefer trospium or solifenacin 5mg) |
| β3-Adrenergic agonist - Mirabegron | Relaxes detrusor smooth muscle via β3 receptor activation | Good alternative when antimuscarinics fail or are not tolerated; raises BP slightly |
| Combination (antimuscarinic + mirabegron) | Additive benefit | For refractory OAB with UUI |
D. Minimally Invasive Procedures
1. Urethral Bulking Agents (Periurethral Injections) - for SUI/ISD
Injected transurethrally or periurethrally to increase urethral closure pressure by increasing the bulk of the submucosa around the sphincter.
Currently FDA-approved agents (Campbell-Walsh-Wein Urology):
| Agent | Material |
|---|---|
| Durasphere | Carbon-coated zirconium beads |
| Macroplastique | Silicone microimplants (polydimethylsiloxane) |
| Coaptite | Calcium hydroxyapatite |
- Suitable for patients unfit for or declining surgery
- Minimally invasive, done under local anesthesia
- Lower success rates than surgery (~30-50% at 2 years); repeat injections may be needed
- Particularly useful in intrinsic sphincter deficiency (ISD) - which is exactly what over-dilation can cause
2. Intradetrusor Botulinum Toxin A (for UUI component)
- OnabotuliumtoxinA (Botox) 100U injected cystoscopically into the detrusor muscle
- Reduces detrusor overactivity and urgency incontinence
- Effective for 6-9 months; repeat injections needed
- Risk: urinary retention (patient should be willing to self-catheterize if needed)
3. Sacral Neuromodulation (InterStim)
- Implanted sacral nerve root stimulator (S3 level)
- Modulates afferent/efferent pathways controlling the bladder and sphincter
- Effective for both UUI and non-obstructive urinary retention
- Consider for refractory cases failing medication and Botox
4. Posterior Tibial Nerve Stimulation (PTNS)
- Percutaneous needle placed near the ankle, stimulates tibial nerve (L4-S3 pathway)
- Effective for UUI/OAB; 12-week course of weekly sessions
- Non-invasive, no implant required
E. Surgical Treatment - for Refractory SUI
These are reserved for SUI that fails conservative treatment and bulking agents, or when incontinence is severe:
| Surgery | Mechanism | Notes |
|---|---|---|
| Midurethral Sling (MUS) - TVT (tension-free vaginal tape) or TOT (transobturator tape) | Polypropylene mesh sling placed under the mid-urethra to restore urethral support | Most widely performed; ~80-90% cure rate; first choice for SUI with urethral hypermobility |
| Pubovaginal Sling (autologous fascia) | Fascial strip placed at bladder neck/proximal urethra; restores support and compression | Preferred when ISD is the primary mechanism (post-dilation injury) or in patients with prior mesh complications |
| Burch Colposuspension | Laparoscopic/open elevation and fixation of bladder neck to Cooper's ligament | Effective when concurrent prolapse repair is performed; ~85% success |
| Artificial Urinary Sphincter (AUS) | Hydraulic cuff placed around the bladder neck/proximal urethra; patient-controlled pump | For severe sphincter deficiency not responding to slings; more common in males but used in females; highly effective but mechanical complications possible |
Practical Treatment Algorithm
Post-dilation incontinence
│
┌─────┴─────┐
Stress UI Urgency UI
│ │
PFMT + Bladder Bladder retraining
retraining + Antimuscarinics /
│ Mirabegron
Pessary / │
vaginal estrogen If refractory:
│ Botox or PTNS
Duloxetine or Sacral neuro-
│ modulation
Bulking agents
│
Surgery:
- Midurethral sling
- Pubovaginal sling
- AUS (severe ISD)
Key point: Post-dilation incontinence that is purely sphincter-related (SUI/ISD) is best addressed with PFMT first → bulking agents → pubovaginal sling or AUS. If urgency/detrusor overactivity is the dominant component (UUI), anticholinergics/mirabegron → Botox → neuromodulation is the pathway.
Sources: Berek & Novak's Gynecology, pp. 1516-1540; Campbell-Walsh-Wein Urology, p. 3814 (Urethral Bulking Agents); Goldman-Cecil Medicine, Table 153 (Stepwise approach to UI); EAU Urethral Strictures Guidelines 2024
This is a shared conversation. Sign in to Orris to start your own chat.